Review Article
Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis
Tzewah V. Leung, PharmD, BCOP, Mitchell E. Hughes, PharmD, BCPS, BCOP, Christine G. Cambareri, PharmD, BCPS, BCOP, Daniel J. Rubin, PharmD, and Beth Eaby-Sandy, MSN, CRNP, OCN®
Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Authors’ disclosures of conflicts of interest are found at the end of this article.
Tzewah V. Leung, PharmD, BCOP, 3400 Civic Center Blvd, West Pavilion, 4th Floor Pharmacy, Philadelphia, PA 19104. E-mail: vivian.leung@uphs.upenn.edu
J Adv Pract Oncol 2018;9(6):614–629 |
https://doi.org/10.6004/jadpro.2018.9.6.4 |
© 2018 Harborside™
ABSTRACT
Abstract
Chemotherapy, and now targeted therapies and immunotherapies, are widely used for the management of patients with all stages of lung cancer. Some challenges present when patients are receiving concomitant hemodialysis for various comorbid conditions. However, this should not immediately rule out a patient for treatment. Many drugs may be safely given to patients who are receiving hemodialysis with the proper dosing schedule and careful monitoring. This article will outline the current literature surrounding the use of these drugs in patients undergoing active hemodialysis while being treated for lung cancer.
For access to the full length article, please
sign in.
